KPV Peptide Dosage Chart, Protocol & Reconstitution Guide (2026)

KPV is a three-amino-acid peptide (lysine-proline-valine) cut from the C-terminus of alpha-MSH. The research community most often discusses it for anti-inflammatory and gut-barrier work, particularly in inflammatory bowel disease (IBD) models.

Animal and laboratory research: KPV is small enough for transport through a gut protein called PepT1. This is why community research discussions often compare oral KPV with subcutaneous (SubQ) use. Human route standards have not been established.

Unlike melanotan-type peptides, KPV does not trigger pigmentation. It uses a different mechanism than the rest of alpha-MSH and skips melanocortin-receptor signaling.

This protocol page is for KPV dosing, vial mixing, and planning. For the broader research view, visit the KPV guide on how it may work, studies, safety notes, and legal status.

The chart below shows calculation examples for commonly discussed KPV research amounts from 200 to 500 mcg. A 5 mg vial mixed with 1 mL and a 10 mg vial mixed with 2 mL both create a concentration of 5,000 mcg per mL. At that concentration, 200 mcg equals 4 units on a U-100 syringe and 500 mcg equals 10 units.

A 10 mg vial contains 10,000 mcg total. Adding 2 mL of bacteriostatic water creates a concentration of 5,000 mcg per mL, or 50 mcg per unit on a U-100 syringe. The table below shows the math for several common research reference amounts.

A 5 mg vial contains 5,000 mcg total. Adding 1 mL of bacteriostatic water creates a concentration of 5,000 mcg per mL, or 50 mcg per unit on a U-100 syringe. This produces the same unit math as a 10 mg vial mixed with 2 mL.

No completed human dose-finding trial defines an official KPV protocol. Research and community planning most often discuss 200–500 mcg per day, but route, frequency, and duration vary. The table below separates community-reported schedules from published evidence and calculation-only content.

KPV reconstitution math depends on the amount in the vial and the amount of liquid added. Convert the vial amount from milligrams to micrograms, divide by the added milliliters, and then calculate the volume needed for the target research amount. The examples below use U-100 syringe units, where 100 units equal 1 mL.

Worked example: A 10 mg vial contains 10,000 mcg. Adding 2 mL creates a concentration of 5,000 mcg/mL. A 300 mcg calculation is 300 ÷ 5,000 = 0.06 mL, which equals 6 units on a U-100 syringe.

Published research does not establish a clinically proven KPV cycle length. Community schedules often use several weeks followed by a review period, but these timelines are anecdotal and should not be treated as validated human protocols.

For four-, six-, eight-, 12-, and 16-week planning examples, reported break periods, study timelines, and vial calculations, read the KPV cycle-length guide.

KPV appears in oral, subcutaneous, and topical research discussions. Published human comparisons have not established which route, dose, or schedule is best.

KPV works differently from most anti-inflammatory compounds. Instead of broadly suppressing the immune system the way steroids do, it targets a specific inflammation switch inside cells. The mechanism is unusually well mapped for a peptide that has not been tested in humans.

PepT1 is a transporter on the surface of intestinal cells that moves di- and tripeptides from the gut into the cell. KPV is small enough to fit. Inflamed gut tissue produces more PepT1, so oral KPV may preferentially concentrate where inflammation is worst (Dalmasso et al. 2008, Gastroenterology).

NF-kB is the master switch that turns on inflammatory gene expression. Preclinical work reports that KPV reduces how long this switch stays "on" and how many inflammatory signals are produced — without the broad immunosuppression of corticosteroids.

Some older articles claim KPV acts on melanocortin receptors. This is incorrect. The 2008 Dalmasso paper showed no melanocortin-receptor signaling, and follow-up work in receptor-knockout mice confirmed KPV still works without those receptors. KPV does not cause tanning or pigmentation changes and should not be confused with melanotan compounds.

The gut-inflammation findings — particularly the PepT1 transport discovery — are the strongest part of the KPV literature. They are still preclinical. No human study has yet confirmed how effective KPV is in people, what an optimal dose looks like, or what the long-term safety profile is.

KPV is studied mainly in anti-inflammatory and gut-barrier models. No completed human trial defines who can use it safely, so this page does not provide personal eligibility advice.

Generally outside research-planning scope: pregnancy and breastfeeding (no safety data), known hypersensitivity to peptide compounds, and active complex infectious disease without clinician oversight (because of overlapping inflammatory and antimicrobial signaling).

Caution areas: active autoimmune disease on prescribed immunomodulators (the interaction has not been studied), and IBD or other inflammatory bowel conditions managed with prescription therapy. KPV should not replace prescribed medication and should be discussed with the treating clinician.

Quality-control caution: KPV is sold as research-use peptide outside FDA-approved channels. Source quality, COA verification, and storage handling vary widely between suppliers.

KPV is generally reported as well-tolerated in animal studies and in community use, but no formal human safety trial has been completed. Long-term safety data does not exist.

Commonly reported effects (community-level, not trial data): mild and transient injection-site irritation, occasional mild headache, and occasional GI upset at higher oral doses.

Pigmentation: KPV is generally modeled as non-pigmenting. It does not bind the melanocortin receptors that drive melanotan-style tanning.

Immune profile: KPV dials down specific inflammatory pathways (notably NF-kB) rather than broadly suppressing the immune system. In animal work this has not produced the infection-susceptibility profile seen with corticosteroids — but this distinction has not been confirmed in human trials.

Quality-control risk: As with any research-use peptide, contamination, underdosing, or incorrect labeling are real risks. Use COA-verified suppliers and inspect every reconstituted vial for clarity before use.

General cautions: Avoid in pregnancy/breastfeeding. Discuss with a clinician if you have active autoimmune disease, complex infectious disease, or are taking prescribed immunomodulators.

KPV is not FDA-approved for any indication.

In materials presented for the July 23, 2026 Pharmacy Compounding Advisory Committee meeting, the FDA proposed that KPV free base and KPV acetate not be added to the 503A Bulks List. KPV remains unapproved. This proposal should not be described as FDA approval or as a general ban on all KPV research.

WADA status: KPV is not a named WADA-prohibited substance. The relevant alpha-MSH-derived compounds covered under WADA rules are different molecules.

Sources for this section include FDA materials for the July 23, 2026 Pharmacy Compounding Advisory Committee meeting and the FDA bulk substances list update. See the Sources & Research section below.

Reconstituted peptide material is commonly stored under refrigeration, but the correct conditions depend on the product and preparation instructions. Follow the label or documentation provided with the material.

No human trial defines a KPV response timeline or standard monitoring plan. Animal and laboratory findings should not be used to predict when a person will notice a result.

Research review: Track the material, route, calculation, storage conditions, and any unexpected change. There is no trial-defined lab panel for KPV, and any health concern needs review by a licensed clinician.

KPV is often compared with BPC-157 and alpha-MSH. In preclinical discussions, KPV is studied for inflammatory signaling, BPC-157 is studied for repair, and alpha-MSH is the parent hormone with broader effects.

KPV should not be confused with melanotan compounds. Pigmentation is not part of KPV's profile.

KPV pairs naturally with repair- and skin-focused peptides. The most-discussed combinations are below.

KPV is usually discussed in inflammation, gut, immune, and skin research. Monitoring focuses on broad inflammatory context, but labs may not capture local skin or gut response.